Bil­lions on the line, No­var­tis and Am­gen ex­change broad­sides as Aimovig part­ner­ship erupts in­to a le­gal war

No­var­tis has had noth­ing but up­beat things to say about their hot new mi­graine drug Aimovig and the reengi­neered col­lab­o­ra­tion pact with Am­gen back in 2017 that gave them half of the lu­cra­tive US mar­ket.

Un­til to­day.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.